By Fineline Cube 
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated trial (ITT) of its radionuclide drug conjugate (RDC) candidate GPN02006. The study, conducted in China, demonstrated the drug’s diagnostic efficacy for hepatocellular carcinoma (HCC).
Trial Details and Results
The prospective, single-center diagnostic study involved over 80 patients with clinically suspected or diagnosed HCC. GPN02006 was used to perform PET/CT or PET/MRI imaging. Results showed that GPN02006 offers high-quality imaging within 30 minutes of administration, meeting the rapid diagnostic needs for HCC. Notably, no drug-related adverse reactions were reported, highlighting its excellent safety profile.
Mechanism and Advantages
GPN02006, co-developed by Wuhan Ruidifu Biotechnology Co., Ltd. and Jecho Biopharmaceuticals Co., Ltd., targets phosphatidylinositol proteoglycan 3 (GPC-3) to achieve precise HCC diagnosis. The drug features an extremely low background signal, high HCC lesion specificity, and superior diagnostic contrast, making it suitable for early lesion localization, treatment response evaluation, and monitoring of recurrence and metastasis.-Fineline Info & Tech